Fourteen children (9 females, 5 males), 10 affected by JIA, 3 by idiopathic uveitis, and 1 by Behçet’s disease, were recruited in Group 1, thus receiving Adalimumab as first anti-TNF-α drug. The gene discussed is TNF; the disease is Behcet disease.